ArticleBMJ open2026
Patient characteristics, treatment patterns and clinical outcomes of immunoglobulin a nephropathy (IgAN) in China: a retrospective cohort study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess patient characteristics, treatment patterns and clinical outcomes of immunoglobulin A nephropathy (IgAN) in China.
designRetrospective cohort study.
settingRegional electronic health records database from Yinzhou District of Ningbo City, China.
participantsA total of 978 adult patients with biopsy-proven primary IgAN diagnosed between 2015 and 2023. PRIMARY AND SECONDARY OUTCOME MEASURES: Baseline characteristics, treatment patterns before and after renal biopsy, and temporal treatment trends were assessed. Clinical outcomes included composite renal events and estimated glomerular filtration rate (eGFR) decline trajectories according to proteinuria levels at biopsy and during follow-up.
resultsMost patients were diagnosed at early chronic kidney disease stages (70.1% stage I-II) but frequently exhibited hypertension (55.0%) and advanced pathological features, with 85.9% classified as Lee grade III-V and 77.8%-98.9% showing M1, E1 or S1 lesions. At biopsy, 65.6% had proteinuria >0.5 g/day. Over a median follow-up of 3 years, 6.7% experienced composite renal events, while 58.2% maintained proteinuria >0.5 g/day. Renin-angiotensin-aldosterone system inhibitors were widely prescribed (91.5%), with increasing use of sodium-glucose cotransporter-2 inhibitors and non-steroidal immunosuppressants and declining corticosteroid use over time. After adjustment for key demographic and clinical factors, persistent proteinuria was associated with higher renal risk and faster eGFR decline.
conclusionsDespite early diagnosis and strong guideline adherence, persistent proteinuria and adverse outcomes remain common, underscoring the need for more effective therapies in IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.